MCID: LPD008
MIFTS: 57

Lipid Metabolism Disorder

Categories: Metabolic diseases

Aliases & Classifications for Lipid Metabolism Disorder

MalaCards integrated aliases for Lipid Metabolism Disorder:

Name: Lipid Metabolism Disorder 12 14
Disorder of Fatty Acid Metabolism 29 69
Lipid Metabolism Disorders 41 69
Dyslipidemia 12 52
Abnormality of Lipid Metabolism 29
Lipid Metabolism, Inborn Errors 42
Fatty Acid Metabolism Disorder 12
Dyslipidemias 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3146
MeSH 42 D008052
ICD10 33 E71.3
UMLS 69 C0023772

Summaries for Lipid Metabolism Disorder

MedlinePlus : 41 metabolism is the process your body uses to make energy from the food you eat. food is made up of proteins, carbohydrates, and fats. chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. your body can use this fuel right away, or it can store the energy in your body tissues. if you have a metabolic disorder, something goes wrong with this process. lipid metabolism disorders, such as gaucher disease and tay-sachs disease, involve lipids. lipids are fats or fat-like substances. they include oils, fatty acids, waxes, and cholesterol. if you have one of these disorders, you may not have enough enzymes to break down lipids. or the enzymes may not work properly and your body can't convert the fats into energy. they cause a harmful amount of lipids to build up in your body. over time, that can damage your cells and tissues, especially in the brain, peripheral nervous system, liver, spleen, and bone marrow. many of these disorders can be very serious, or sometimes even fatal. these disorders are inherited. newborn babies get screened for some of them, using blood tests. if there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. enzyme replacement therapies can help with a few of these disorders. for others, there is no treatment. medicines, blood transfusions, and other procedures may help with complications.

MalaCards based summary : Lipid Metabolism Disorder, also known as disorder of fatty acid metabolism, is related to gaucher's disease and sitosterolemia. An important gene associated with Lipid Metabolism Disorder is RBP4 (Retinol Binding Protein 4), and among its related pathways/superpathways are Metabolism and Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha). The drugs Simvastatin and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and endothelial, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Disease Ontology : 12 An inherited metabolic disorder that involves the creation and degradation of lipids.

Related Diseases for Lipid Metabolism Disorder

Diseases related to Lipid Metabolism Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 132)
id Related Disease Score Top Affiliating Genes
1 gaucher's disease 31.7 APOB CRP INS
2 sitosterolemia 31.6 APOB HMGCR MTTP
3 lipodystrophy, familial partial, type 2 31.6 INS LEP
4 failure to thrive and dyslipidemia caused by citrin deficiency 11.9
5 hypoalphalipoproteinemia 11.0
6 aromatase deficiency 10.9
7 fatty liver disease, nonalcoholic 1 10.9
8 hyperlipoproteinemia, type iii 10.8
9 bietti crystalline corneoretinal dystrophy 10.7
10 achard thiers syndrome 10.7 ADIPOQ PPARG
11 lipodystrophy, familial partial, type 3 10.7
12 gallbladder disease 1 10.7
13 citrullinemia, type ii, neonatal-onset 10.7
14 lipodystrophy, familial partial, type 6 10.7
15 prediabetes syndrome 10.7
16 hypolipoproteinemia 10.7
17 acyl-coa dehydrogenase, medium chain, deficiency of 10.7
18 chylomicron retention disease 10.7
19 cpt deficiency, hepatic, type ia 10.7
20 acyl-coa dehydrogenase, short-chain, deficiency of 10.7
21 tay-sachs disease 10.7
22 barth syndrome 10.7
23 vlcad deficiency 10.7
24 carnitine palmitoyltransferase ii deficiency 10.7
25 steroid inherited metabolic disorder 10.7
26 xk aprosencephaly 10.7 APOB APOE
27 chronic fungal otitis externa 10.7 CRP INS
28 hypercholesterolemia, due to ligand-defective apo b 10.7 APOB APOE
29 legg-calve-perthes disease 10.6 APOA1 APOB LEP
30 acquired hypoprothrombinemia 10.6 ADIPOQ LEP
31 epilepsy, familial focal, with variable foci 3 10.6 LIPC LPL
32 delta-1-pyrroline-5-carboxylate dehydrogenase deficiency 10.6 APOB APOE HMGCR
33 neurogenic arthropathy 10.6 ADIPOQ INS LEP
34 mucinoses 10.5 ADIPOQ INS LEP
35 lissencephaly 10.5 INS LEP PPARG
36 familial osteochondritis dissecans 10.5 APOA1 APOE
37 fetal parvovirus syndrome 10.5 APOA1 APOB INS LEP
38 idiopathic juxtafoveal retinal telangiectasia 10.5 ADIPOQ INS PPARA PPARG
39 hyperinsulinemic hypoglycemia, familial, 4 10.5 ADIPOQ INS PPARA PPARG
40 antidepressant type abuse 10.5 ADIPOQ INS LEP RBP4
41 carnitine deficiency, systemic primary 10.5 APOA1 APOB MTTP
42 otospondylomegaepiphyseal dysplasia 10.5 APOA1 APOB SERPINE1
43 mental retardation, autosomal dominant 45 10.4 APOB APOE LPA
44 chondroma 10.4 CRP INS LEP
45 myh-9 related disease 10.4 INS LEP
46 atopic dermatitis 3 10.4 APOC3 LPA
47 dientamoebiasis 10.4 ADIPOQ INS LEP PPARA
48 amyloidosis nodular localized cutaneous 10.4 APOA1 CRP LPA
49 leigh syndrome with leukodystrophy 10.4 ADIPOQ LEP
50 mature gastric teratoma 10.4 ADIPOQ INS LEP PPARG

Comorbidity relations with Lipid Metabolism Disorder via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Hypertension, Essential
Intermediate Coronary Syndrome Ischemic Heart Disease

Graphical network of the top 20 diseases related to Lipid Metabolism Disorder:



Diseases related to Lipid Metabolism Disorder

Symptoms & Phenotypes for Lipid Metabolism Disorder

GenomeRNAi Phenotypes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.65 HMGCR LIPC LPA LPL APOA1 APOA5
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE LPL

MGI Mouse Phenotypes related to Lipid Metabolism Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 ADIPOQ APOA1 APOA5 APOB APOE COG2
2 cardiovascular system MP:0005385 10.18 LEP LPL MTTP PPARA PPARG RBP4
3 growth/size/body region MP:0005378 10.1 ADIPOQ APOB APOE COG2 HMGCR INS
4 adipose tissue MP:0005375 10.01 ADIPOQ APOE INS LEP LPL PPARA
5 integument MP:0010771 9.81 ADIPOQ APOA1 APOE INS LEP LPL
6 liver/biliary system MP:0005370 9.73 LEP LPL MTTP PPARA PPARG SERPINE1
7 muscle MP:0005369 9.28 ADIPOQ APOB APOE INS LEP LPL

Drugs & Therapeutics for Lipid Metabolism Disorder

Drugs for Lipid Metabolism Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 746)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
2
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
3
Cilostazol Approved Phase 4,Phase 3,Phase 1 73963-72-1 2754
4
Probucol Approved Phase 4,Phase 3 23288-49-5 4912
5
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
6
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
7
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1 49562-28-9 3339
8
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
9
Thrombin Approved Phase 4
10
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
11
Pravastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 81093-37-0 54687
12
Saxagliptin Approved Phase 4 361442-04-8 11243969
13
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2 136470-78-5 65140 441300
14
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
15
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
16
Lopinavir Approved Phase 4,Phase 2,Phase 1 192725-17-0 92727
17
Nevirapine Approved Phase 4,Phase 2 129618-40-2 4463
18
Zidovudine Approved Phase 4,Phase 2 30516-87-1 35370
19
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
20
Testosterone Approved, Investigational Phase 4,Phase 2 58-22-0 6013
21
Liraglutide Approved Phase 4,Phase 2 204656-20-2 44147092
22
Mitiglinide Approved, Investigational Phase 4 145375-43-5 3047758
23
Gemfibrozil Approved Phase 4,Phase 1 25812-30-0 3463
24
Pitavastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 147511-69-1, 147526-32-7 6366718 5282452
25
Acarbose Approved, Investigational Phase 4,Phase 3 56180-94-0 441184
26
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
27
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 1 132539-06-1 4585
28
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
29
Bezafibrate Approved Phase 4,Phase 3,Phase 2 41859-67-0 39042
30
Lovastatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75330-75-5 53232
31
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
32
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
33
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 128794-94-5 5281078
34
Mycophenolic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 24280-93-1 446541
35
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 1 154598-52-4 64139
36
Darunavir Approved Phase 4,Phase 1 635728-49-3, 206361-99-1 213039
37
Magnesium oxide Approved Phase 4,Phase 3,Phase 2 1309-48-4 14792
38
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 1 144701-48-4 65999
39
Zinc Approved Phase 4,Phase 2,Phase 3,Early Phase 1 7440-66-6 32051 23994
40
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
41
Repaglinide Approved, Investigational Phase 4,Phase 3 135062-02-1 65981
42
Linagliptin Approved Phase 4 668270-12-0 10096344
43 Fenofibric acid Approved Phase 4,Phase 3,Phase 1 42017-89-0
44
Hydroxocobalamin Approved Phase 4,Phase 1,Phase 2 13422-51-0 11953898 5460373 44475014
45
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1 88150-42-9 2162
46
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
47
Irbesartan Approved, Investigational Phase 4,Phase 3 138402-11-6 3749
48
Colestipol Approved Phase 4 26658-42-4, 50925-79-6 62816
49
Everolimus Approved Phase 4,Phase 3,Phase 1 159351-69-6 6442177
50
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show top 50) (show all 3018)

id Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin Unknown status NCT01613729 Phase 4 Rosuvastatin 5 mg;Rosuvastatin 10 mg
2 An Open-Label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin Unknown status NCT00678743 Phase 4 Omacor + simvastatin
3 Trial to Assess the Effects of P-OM3 on LDL-C in Subjects With Primary Hypercholesterolemia Unknown status NCT00746811 Phase 4 P-OM3;Placebo
4 Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia Unknown status NCT00972829 Phase 4 Rosuvastatin;Ezetimibe
5 To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Unknown status NCT02098460 Phase 4 Atorvastatin, Probucol, Cilostazol
6 The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels Unknown status NCT01712867 Phase 4
7 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
8 Fluvastatin After Heart Transplantation Unknown status NCT00421005 Phase 4 fluvastatin
9 Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy? Unknown status NCT00295373 Phase 4 Rosuvastatin
10 Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia Unknown status NCT01849185 Phase 4
11 Triglyceride Lowering Study Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
12 The HDL Particle Protection Study Unknown status NCT02125682 Phase 4 atovastatin 10 mg/day;Atorvastatin 80 mg/day
13 Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia Unknown status NCT01010516 Phase 4 High-dose rosuvastatin;Statin plus fenofibrate;Statin plus niacin ER/laropiprant
14 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
15 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
16 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
17 Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study) Unknown status NCT02035644 Phase 4 Jinlida granules;placebo granules
18 The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients Unknown status NCT00758927 Phase 4 Omega-3 acid 4 grams per day;Placebo control
19 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
20 Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes Unknown status NCT01322711 Phase 4 Atorvastatin;Placebo
21 Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia Unknown status NCT01480687 Phase 4 Ciprofibrate
22 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
23 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Unknown status NCT00487630 Phase 4 recombinant alpha-galactosidase A
24 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
25 Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume Unknown status NCT01382277 Phase 4 Rosuvastatin
26 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
27 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
28 Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH) Unknown status NCT00885872 Phase 4 Rosuvastatin (Crestor)
29 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
30 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
31 Effect of Rosuvastatin Therapy on HDL2 Level Unknown status NCT02593487 Phase 4 Rosuvastatin 10mg/d group;Rosuvastatin 20mg/d group
32 Effects of DPP-4 Inhibition on Triglycerides Unknown status NCT01527747 Phase 4 Saxagliptin
33 SHARE: Simple HAART With Abacavir, Reyataz, and Epivir Unknown status NCT00426296 Phase 4 atazanavir (Reyataz);ritonavir (Norvir)
34 The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control Unknown status NCT00282659 Phase 4 magnesium L-lactate
35 MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) Unknown status NCT00122226 Phase 4 Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine
36 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
37 Multiple Grain in Type 2 Diabetes Unknown status NCT00337337 Phase 4
38 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
39 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
40 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
41 Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
42 Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes Unknown status NCT01185236 Phase 4 simvastatin/ezetimibe;atorvastatin 20mg
43 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
44 Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin. Unknown status NCT00404599 Phase 4 atrorvastatin 10mg;simvastatin 40mg
45 Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED) Completed NCT00651963 Phase 4 ezetimibe
46 Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Completed NCT01551173 Phase 4 Fluvastatin sodium
47 Pharmacological Regulation of Fat Transport in Metabolic Syndrome Completed NCT00632840 Phase 4 Atorvastatin and fenofibrate
48 Regulation of Lipoprotein Transport in Metabolic Syndrome Completed NCT00841217 Phase 4 GW501516;placebo pill
49 Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes Completed NCT02689765 Phase 4
50 Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study Completed NCT00701727 Phase 4 ezetimibe;Placebo

Search NIH Clinical Center for Lipid Metabolism Disorder

Cochrane evidence based reviews: lipid metabolism, inborn errors

Genetic Tests for Lipid Metabolism Disorder

Genetic tests related to Lipid Metabolism Disorder:

id Genetic test Affiliating Genes
1 Disorder of Fatty Acid Metabolism 29
2 Abnormality of Lipid Metabolism 29

Anatomical Context for Lipid Metabolism Disorder

MalaCards organs/tissues related to Lipid Metabolism Disorder:

39
Heart, Liver, Endothelial, Testes, Bone, Kidney, Bone Marrow

Publications for Lipid Metabolism Disorder

Articles related to Lipid Metabolism Disorder:

(show all 31)
id Title Authors Year
1
Association of SREBP2 gene polymorphisms with the risk of osteonecrosis of the femoral head relates to gene expression and lipid metabolism disorders. ( 28901487 )
2017
2
Magnesium isoglycyrrhizinate blocks fructose-induced hepatic NF-I_B/NLRP3 inflammasome activation and lipid metabolism disorder. ( 28526339 )
2017
3
Maternal chromium restriction modulates miRNA profiles related to lipid metabolism disorder in mice offspring. ( 28669221 )
2017
4
Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4I+ miR122 Pathway. ( 27011261 )
2016
5
Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome. ( 26868993 )
2016
6
HNF-4I+ regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in Type 2 diabetic mice and in palmitate-treated HepG2 cells. ( 27592052 )
2016
7
Oral tributyrin prevents endotoxin-induced lipid metabolism disorder. ( 28531464 )
2015
8
Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob/ob mice. ( 25732571 )
2015
9
Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway. ( 25885422 )
2015
10
Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. ( 26071454 )
2015
11
[Genetically determined lipid metabolism disorders due to oral intake of technogenic hyperchlorination products]. ( 26596112 )
2015
12
Angelica sinensis polysaccharide regulates glucose and lipid metabolism disorder in prediabetic and streptozotocin-induced diabetic mice through the elevation of glycogen levels and reduction of inflammatory factors. ( 25630053 )
2015
13
L-Carnitine intake prevents irregular feeding-induced obesity and lipid metabolism disorder. ( 25445284 )
2015
14
Ameliorating effect of mother tincture of Syzygium jambolanum on carbohydrate and lipid metabolic disorders in streptozotocin-induced diabetic rat: Homeopathic remedy. ( 23633838 )
2013
15
Green tea extract containing a highly absorbent catechin prevents diet-induced lipid metabolism disorder. ( 24067358 )
2013
16
Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy. ( 22213519 )
2012
17
Quercetin Protects against Cadmium-Induced Renal Uric Acid Transport System Alteration and Lipid Metabolism Disorder in Rats. ( 22690247 )
2012
18
Abnormal barrier function in the pathogenesis of ichthyosis: therapeutic implications for lipid metabolic disorders. ( 22507046 )
2012
19
The model of rat lipid metabolism disorder induced by chronic stress accompanying high-fat-diet. ( 21871127 )
2011
20
Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. ( 21093950 )
2011
21
Fat and cholesterol diet induced lipid metabolic disorders and insulin resistance in rabbit. ( 19301228 )
2009
22
Chanarin-Dorfman syndrome: clinical features of a rare lipid metabolism disorder. ( 19250403 )
2009
23
[Carbohydrate and lipid metabolism disorders in obese children and adolescents]. ( 15858253 )
2004
24
[Interconnection between insulin resistance and lipid metabolism disorders in obese patients]. ( 12469622 )
2002
25
[Pharmacologic treatment of lipid metabolism disorders]. ( 9214849 )
1996
26
[The evaluation of a method for determining apolipoproteins as a sensitive indicator in assessing lipid metabolic disorder in a population at risk for essential arterial hypertension (EAHT)]. ( 9455355 )
1995
27
[Lipid metabolic disorders and lipid peroxidation in patients with the nephrotic syndrome]. ( 8079411 )
1994
28
[Relationship between lipid metabolism disorders and age of first manifestations of coronary heart disease]. ( 1509793 )
1992
29
[Pathophysiology and therapy of lipid metabolism disorders in kidney diseases]. ( 1921228 )
1991
30
[Restriction polymorphism in patients with lipid metabolism disorders and ischemic heart disease]. ( 1979835 )
1990
31
A lipid metabolic disorder: disseminated lipogranulomatosis; a syndrome with similarity to, and important difference from, Niemann-Pick and Hand-SchA1ller-Christian disease. ( 12975849 )
1952

Variations for Lipid Metabolism Disorder

Expression for Lipid Metabolism Disorder

Search GEO for disease gene expression data for Lipid Metabolism Disorder.

Pathways for Lipid Metabolism Disorder

Pathways related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
2
Show member pathways
12.81 ADIPOQ APOA1 APOA5 HMGCR LEP LPL
3
Show member pathways
12.6 APOA1 APOB APOC3 APOE LPL RBP4
4
Show member pathways
12.36 ADIPOQ HMGCR INS LEP PPARG
5
Show member pathways
12.3 APOA1 APOB APOC3 APOE LPL RBP4
7
Show member pathways
12.19 APOA1 APOA5 APOB APOC3 APOE CETP
8 11.92 ADIPOQ INS LEP LPL PPARA PPARG
9 11.86 ADIPOQ INS LEP LPL PPARG
10
Show member pathways
11.77 APOA1 APOB APOE
11 11.63 HMGCR INS LPL PPARG RBP4
12 11.58 ADIPOQ LEP PPARA
13 11.56 ADIPOQ APOA1 APOA5 APOC3 LPL PPARA
14
Show member pathways
11.38 APOA1 APOB MTTP
15
Show member pathways
11.15 APOA1 APOA5 APOB APOC3 APOE CETP
16 11.12 APOA1 APOA5 APOC3 PPARA
17 11.11 ADIPOQ LEP PPARG
18 11.04 ADIPOQ LEP PPARG

GO Terms for Lipid Metabolism Disorder

Cellular components related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.98 APOA1 APOA5 APOB APOE INS LIPC
2 early endosome GO:0005769 9.84 APOA1 APOB APOC3 APOE
3 high-density lipoprotein particle GO:0034364 9.77 APOA1 APOA5 APOE CETP LIPC
4 low-density lipoprotein particle GO:0034362 9.71 APOA1 APOA5 APOB APOE
5 extracellular matrix GO:0031012 9.67 APOE LPL SERPINE1
6 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
7 intermediate-density lipoprotein particle GO:0034363 9.56 APOA1 APOB APOC3 APOE
8 endosome lumen GO:0031904 9.55 APOB INS
9 spherical high-density lipoprotein particle GO:0034366 9.51 APOA1 APOC3
10 very-low-density lipoprotein particle GO:0034361 9.43 APOA1 APOA5 APOB APOC3 APOE LPL
11 discoidal high-density lipoprotein particle GO:0034365 9.18 APOA1
12 chylomicron GO:0042627 9.1 APOA1 APOA5 APOB APOC3 APOE LPL
13 extracellular exosome GO:0070062 10.22 ADIPOQ APOA1 APOB APOC3 APOE CETP
14 extracellular region GO:0005576 10.2 ADIPOQ APOA1 APOA5 APOB APOC3 APOE
15 extracellular space GO:0005615 10 ADIPOQ APOA1 APOA5 APOB APOC3 APOE

Biological processes related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.98 ADIPOQ HMGCR LEP RBP4
2 lipid catabolic process GO:0016042 9.98 APOB APOC3 LIPC LPL
3 negative regulation of inflammatory response GO:0050728 9.97 ADIPOQ APOA1 APOE PPARA
4 circadian rhythm GO:0007623 9.96 ADIPOQ LEP MTTP SERPINE1
5 cholesterol efflux GO:0033344 9.96 APOA1 APOA5 APOB APOC3 APOE
6 high-density lipoprotein particle remodeling GO:0034375 9.93 APOA1 APOC3 APOE CETP LIPC
7 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.91 ADIPOQ CETP CRP PPARA PPARG
8 glucose metabolic process GO:0006006 9.9 ADIPOQ INS LEP
9 cholesterol transport GO:0030301 9.89 APOA1 APOB CETP LIPC
10 low-density lipoprotein particle remodeling GO:0034374 9.89 APOB APOE CETP LIPC LPA
11 phospholipid transport GO:0015914 9.88 APOA1 CETP MTTP
12 phospholipid efflux GO:0033700 9.88 APOA1 APOA5 APOC3 APOE
13 chylomicron remnant clearance GO:0034382 9.88 APOB APOC3 APOE LIPC
14 negative regulation of MAP kinase activity GO:0043407 9.87 ADIPOQ APOE HMGCR
15 cholesterol biosynthetic process GO:0006695 9.87 APOA1 APOA5 HMGCR
16 very-low-density lipoprotein particle remodeling GO:0034372 9.87 APOE CETP LIPC LPL
17 triglyceride homeostasis GO:0070328 9.87 APOA1 APOA5 APOC3 APOE CETP LIPC
18 lipid homeostasis GO:0055088 9.85 APOE CETP PPARG
19 chylomicron assembly GO:0034378 9.85 APOA1 APOB APOC3 APOE MTTP
20 reverse cholesterol transport GO:0043691 9.85 APOA1 APOA5 APOC3 APOE CETP LIPC
21 lipoprotein transport GO:0042953 9.83 APOB MTTP PPARG
22 high-density lipoprotein particle assembly GO:0034380 9.83 APOA1 APOA5 APOE
23 chylomicron remodeling GO:0034371 9.83 APOA1 APOB APOC3 APOE LPL
24 very-low-density lipoprotein particle assembly GO:0034379 9.82 APOB APOC3 MTTP
25 positive regulation of cholesterol esterification GO:0010873 9.82 APOA1 APOA5 APOE
26 neuron projection regeneration GO:0031102 9.81 APOA1 APOA5 APOE
27 regulation of Cdc42 protein signal transduction GO:0032489 9.8 APOA1 APOC3 APOE
28 lipoprotein metabolic process GO:0042157 9.8 APOA1 APOA5 APOB APOC3 APOE MTTP
29 lipoprotein biosynthetic process GO:0042158 9.79 APOA1 APOB APOE
30 regulation of intestinal cholesterol absorption GO:0030300 9.78 APOA1 APOA5 LEP
31 lipid metabolic process GO:0006629 9.77 APOA1 APOB APOC3 APOE CETP HMGCR
32 negative regulation of lipid catabolic process GO:0050995 9.76 APOC3 INS
33 positive regulation of cellular protein metabolic process GO:0032270 9.76 ADIPOQ INS
34 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.75 APOB LPL
35 regulation of fat cell differentiation GO:0045598 9.75 LEP PPARG
36 fatty acid oxidation GO:0019395 9.75 ADIPOQ PPARG
37 negative regulation of wound healing GO:0061045 9.75 HMGCR SERPINE1
38 positive regulation of cholesterol efflux GO:0010875 9.75 ADIPOQ APOE
39 negative regulation of gluconeogenesis GO:0045721 9.75 ADIPOQ INS
40 negative regulation of smooth muscle cell migration GO:0014912 9.75 ADIPOQ SERPINE1
41 negative regulation of blood coagulation GO:0030195 9.74 APOE SERPINE1
42 positive regulation of insulin receptor signaling pathway GO:0046628 9.74 INS LEP
43 fatty acid homeostasis GO:0055089 9.74 APOE INS
44 long-chain fatty acid transport GO:0015909 9.74 APOE PPARG
45 phosphatidylcholine metabolic process GO:0046470 9.74 APOA5 CETP
46 positive regulation of lipid biosynthetic process GO:0046889 9.74 APOE INS
47 positive regulation of fatty acid biosynthetic process GO:0045723 9.74 APOA1 APOA5
48 regulation of lipoprotein lipase activity GO:0051004 9.73 LIPC LPL
49 response to dietary excess GO:0002021 9.73 APOE LEP
50 positive regulation of lipoprotein lipase activity GO:0051006 9.73 APOA1 APOA5

Molecular functions related to Lipid Metabolism Disorder according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.88 APOA5 APOB APOE LIPC LPA LPL
2 phospholipid binding GO:0005543 9.83 APOA1 APOA5 APOB APOC3 APOE
3 lipid binding GO:0008289 9.76 APOA1 APOA5 APOB APOC3 APOE CETP
4 phosphatidylcholine binding GO:0031210 9.67 APOA1 APOA5 CETP
5 low-density lipoprotein particle receptor binding GO:0050750 9.67 APOA5 APOB APOE CRP
6 phospholipid transporter activity GO:0005548 9.65 APOA1 CETP MTTP
7 cholesterol binding GO:0015485 9.65 APOA1 APOA5 APOC3 APOE CETP
8 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.63 APOA1 APOA5 APOE
9 apolipoprotein binding GO:0034185 9.62 LIPC LPA LPL MTTP
10 low-density lipoprotein particle binding GO:0030169 9.58 CRP LIPC
11 phospholipase activity GO:0004620 9.57 LIPC LPL
12 lipase binding GO:0035473 9.56 APOA5 APOB
13 lipase inhibitor activity GO:0055102 9.55 APOA1 APOC3
14 lipoprotein particle binding GO:0071813 9.54 APOA1 APOE
15 high-density lipoprotein particle receptor binding GO:0070653 9.52 APOA1 APOC3
16 triglyceride binding GO:0017129 9.51 CETP LPL
17 lipid transporter activity GO:0005319 9.35 APOA1 APOB APOE CETP MTTP
18 cholesterol transporter activity GO:0017127 9.02 APOA1 APOA5 APOB APOE CETP

Sources for Lipid Metabolism Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....